| | SCD/MCI (n=1418) | AD dementia (n=1179) | p-value |
|---|
Age | 63±7 | 65±7 | <0.001 |
Sex, female | 532 (38%) | 624 (53%) | <0.001 |
MMSE | 27±2 | 20±5 | <0.001 |
Diagnoses |
SCD | 836 (59%) | | |
MCI | 582 (41%) | | |
NPI | 10±9 | 12±9 | <0.001 |
CCI | 2.5±1.4 | 3.6±1.3 | <0.001 |
APOE e4 carrier | 618 (58%) | 751 (53%) | <0.001 |
MRI |
GCA | 0.5±0.6 | 1.1±0.6 | <0.001 |
MTA | 0.6±0.6 | 1.4±0.7 | <0.001 |
WMH | 0.9±0.8 | 1.0±0.7 | <0.001 |
CSF, pg/ml |
Aβ42 | 1394±498 | 749±274 | <0.001 |
p-tau | 21±12 | 35±16 | <0.001 |
- Data is represented as mean±SD, median (range) or n (%)
- AD Alzheimer’s disease, SCD subjective cognitive decline, MCI= mild cognitive impairment, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory, CCI Charlson Comorbidity Index, MRI magnetic resonance imaging, GCA global cortical atrophy (0–3), MTA medial temporal lobe atrophy (0–4), WMH white matter hyperintensities (0–3), CSF cerebrospinal fluid, Aβ42 β-Amyloid 1–42, p-tau Tau phosphorylated at threonine 181. CSF values were bridged to Elecsys value
